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Abstract
Advanced and metastatic cancer has a complex diagnostic and management profile that places a heavy long-term burden on
patients and healthcare systems. Little attention has been given to patients’ experiences across their entire clinical journey.
Using a qualitative, longitudinal methodology over a ten-month period, we examined the symptom-to-outcome trajectories of
seven people attending a medical oncology clinic at a large, public tertiary referral center in Sydney, Australia. Rather than
care being experienced as a largely linear progression through diagnosis, treatment and onto surveillance in which life may
return to ‘normal’, participants are embedded in a cyclical clinical pathway. Recurrence or metastases are not a matter of ‘if’
but ‘when’. This model of the patient journey points to a need for longitudinal, person-centered services to support the
growing population of people with melanoma.
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Introduction
A model of the clinical journey experienced by particular
patient populations from symptom identification to
outcome can help healthcare providers to plan appropriate
and supportive care.1 There is a gap in qualitative research
that examines and represents patients’ experiences of their
clinical journeys. Our research seeks to address that gap.
Most research on patient experience is cross-sectional,
taking soundings of the care received at specific points in
time and place. The few longitudinal studies of progressive
patient experience in the context of cancer typically
examine specific aspects of care, such as supportive care,2
psychosocial needs,3 or more defined domains such as
quality of life status4 and informational needs.5
Our study aims to add value to this body of literature by
understanding how a patient cohort experiences different
phases in the overall clinical management of their disease.
We investigated the healthcare experiences of people with
advanced and metastatic melanoma. Melanoma is a cancer
of the pigment cells of the skin. There is evidence that
while the incidence of cancer overall is decreasing, cases of
melanoma are increasing.6 In its rising prevalence, and also
in light of the aggressive and recurrent nature of the
disease, a multitude of services and healthcare settings are
implicated in the pathways to treatment, follow-up and

palliative care. Melanoma is increasingly being
conceptualized as a chronic public healthcare problem.7-10
Earlier work investigating over 200 web-based personal
accounts written by people with melanoma established a
meta-view of the healthcare journeys of people with
varying stages of melanoma.11 The meta-view identified
key phases of the personal patient journey in the
progression of health care-events related to disease
management. These phases were characterized by illdefined symptom identification, problematic diagnosis,
disfiguring treatment, psychological issues related to
lifestyle and sun exposure, longitudinal surveillance
requirements and, for some patients, recurrence or
metastases. We know from that study that the values and
principles of patient-centered care, which are to support
people in understanding and managing their own health,
may not be consistently applied throughout key phases of
the melanoma healthcare journey.
Advanced and metastatic stages of melanoma, involving
spread to distant lymph nodes or organs such as the lungs,
liver, brain or bone, create a different kind of journey.
Visible skin changes that clue people into the possible
presence of early stage cutaneous melanoma are not
necessarily present in metastatic melanoma. The spread to
organs may not be detected until serious physical
manifestations are present. Symptom detection, diagnostic
pathways, treatment and follow-up care take place in a life-
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threatening context.12 In order to understand these
patients better and provide targeted support and care, we
need to comprehend and model their journeys. In this
paper we investigate a potentially generalisable model of
the patient journey for people with advanced or metastatic
melanoma.

Method
Participants

Our participants were drawn from a population of people
attending medical oncology clinics at a public tertiary
referral center in Sydney, Australia. Potential participants
were being seen by an oncologist for the disease
management of tumours suspected or confirmed to be
melanomas.
The inclusion criteria were patients who had a potential or
confirmed diagnosis of advanced or metastatic malignant
melanoma, over 18 years of age and English-speaking. The
period of recruitment was six months, from November
2015 to May 2016. Prospective participants were patients
attending for the first time, or ongoing patients of the
clinic. Although patients were cared for by multiple
doctors, nurses, allied health staff and other specialists, all
potential participants were patients of one medical
oncologist.

Recruitment

Target participants were screened by the medical
oncologist ahead of the scheduled clinic visit. Where

eligible, the oncologist would briefly describe the study
and ask the patients if they were interested in meeting with
the field researcher. If the patient agreed, the researcher
met the patient separately, describing the study and
seeking informed consent. Nine (9) participants agreed to
join the study and to the publication of de-identified study
findings. Two participants died before they could take part
in the initial interviews. The others participated in an initial
interview of at least 20 minutes in length. Enrolees agreed
to be shadowed by the field researcher during clinical
consultations and treatments, and to ongoing interviews
either in person in a setting of their choice or by phone.
The study ensued over the ten-month period from
November 2015 to September 2016, dictated by the
personal and health needs of the participants and the
logistics of doing in-depth social research of this kind. One
participant was found after some weeks into the study to
have been misdiagnosed; what was thought initially to be a
malignant melanoma on the back of his eye was found not
to be. Data collected on that participant to the point of
diagnosis have been included because his perspective
throughout was that he had a melanoma recurrence, and
his experiences were thus from the point of view of
someone with melanoma.

Participants’ characteristics

Table 1 presents the key demographic characteristics of
the seven study participants and the status of their health
at diagnosis.

Table 1. Participants’ demographic profiles and health histories
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Participant

Gender

Age*

Stage1

Melanoma/
tumour

Length of time
since previous
melanoma
20 years

PA

F

75+

4

lungs, stomach,
skull & brain

PB

M

75+

4

12 years

PC

M

25+

3-4

left leg lymph
nodes,
lung
right arm lymph
nodes

PD

F

65+

4

stomach, lung,
liver

4.5 years

PE

M

85+

1/4

eye

N/A

PF

M

70+

4

rib, spine, kidney

2 years

PG

M

70+

4

lung, pancreas

4 years

2 months

How latest diagnosis occurred
After weeks of becoming forgetful
and confused, PA suffered strokelike symptoms and was taken to
hospital where investigations led to
the identification of tumours
Ultrasound for deep vein
thrombosis (DVTs) identified
enlarged lymph glands
Enlarged lymph nodes were
identified in first surveillance scan
after melanoma on back had been
excised
Fell at home, taken to hospital,
investigations led to the
identification of tumours
Scheduled cataract examination
identified lump
Investigation of ongoing pain from
broken rib led to the identification
of tumours
Investigation of abdominal pain led
to the identification of tumours
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Data collection

We employed the methodology of interpretive description
to collect and analyse our data.13 Interpretive description
takes a social constructivist and naturalistic approach. The
methodology emerged from social science and has been
applied most often in nursing research and is intended to
generate knowledge that can be translated into practice
and policy.14 Interpretive description is a “secondgeneration” qualitative approach:15 it promotes a
multidisciplinary research agenda in investigating
“complex experiential clinical/practical phenomena”,16
drawing on methodological principles of grounded theory,
ethnography and phenomenology.
Data comprised transcripts of interviews with participants,
observational field notes and medical information
contributed by the supervising oncologist. This
triangulated data collection helped form meta-views of
what happened as participants pursued their longitudinal
goal of resolving the threats to their lives. Further details
on methods are provided elsewhere.17
Interviews were semi-structured, supported by an
interview guide, encouraging an open dialogue and
allowing participants to move between ‘question and
answer’ mode and ‘story-telling’ mode with the aid of
prompt questions. A key prompt word ‘journey’ was used
to communicate that the study was interested in the past,
present and imagined future of participants’ healthcare
experiences.

Analysis

Data were downloaded into the software package
NVivo10 (QSR International). The analytic procedures in
interpretive description methodology “capitalize on such
processes as synthesizing, theorizing and recontextualizing
rather than simply sorting and coding”.18 We coded textual
data into themes and iteratively coded the elements and

properties of participants’ descriptions and reflections,
classifying them into interpretable categories, mapped
progressively into a study framework.

Results
The analysis created a meta-view (see Figure 1); an
aggregated narrative of the healthcare journeys of
participants structured into four pivotal shifts in patient
experience: Initiation; Identification; Action; and
Adaption. A significant feature of this meta-view is its
circular dynamic pointing to profound and unending
dependence on the healthcare system. This contrasts with
the ideal experience of healthcare services as a
fundamentally linear journey from diagnosis to cure or
stability of disease. In this section we report the shifting
phases of experiences that define this circular meta-view.
1. Initiation: Seeking medical help
Six of the seven participants had been treated for a
primary melanoma in the past. They had completed their
long-term surveillance programs and believed they were
clear of disease. The reasons they were seeking medical
care this time did not relate to melanoma. They were
seeking care for: suspected hernia in the groin (PB);
confusion and forgetfulness (PA); concern about deep
vein thrombosis (DVT) (PB); a fall down a flight of stairs
(PD); detection of a lump on the eye during a cataract
examination (PE); increasing pain from a fractured rib
(PF) and; stomach pain (PG). The final participant (PC)
was still in the care pathway for a primary melanoma when
enlarged lymph nodes were diagnosed.
Decisions about seeking care
Personal values and beliefs about health management
feature strongly. Some participants, such as PB and PG,
were quick to seek medical care for health concerns. Given

Figure 1. A meta-view of the clinical trajectory experienced by people with advanced and metastatic melanoma
Initiation: Seeking medical
help to resolve heath concerns

Adaption: Tumour
surveillance, ongoing
treatment and side effects

Identification: Complex
investigations leading to
diagnosis

Action: Treatment,
palliation and threat of
death
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a history of DVT and a discomfort in his left groin prior
to an upcoming flight, PB organized a pre-emptive
ultrasound. PG had decided that a recent episode of
sudden and severe stomach pain, though resolved and not
ongoing, was worthy of further investigation.
Other participants delayed seeking healthcare. PA believed
that her ongoing bouts of confusion and forgetfulness
indicated stress brought on by current circumstances in
her life. She rationalized that the stress was a temporary
condition and there was no reason to seek medical advice.
PB had been told by a clinician to expect ongoing pain
from a fractured rib; though the pain was intensifying, he
valued himself as a stoic person and rationalized that since
he had an upcoming appointment with a specialist for
another health condition, he could wait until then to seek
advice. PC described scratching an area on his back for six
months before seeing his doctor because he was
distracted, dealing with complex personal issues.
2. Identification: Complex investigations leading to
diagnosis
This phase was characterized by multiple investigations of
possible diagnoses, eventually concluding that a previous
melanoma had recurred, advanced or metastasized.
Further investigations were often required, including
proto-oncogene B-Raf (BRAF) gene mutation testing.
Physical and psychosocial impact of investigations and consultations
Participants noted complex and sometimes confusing
pathways to diagnosis, involving logistical challenges,
substantial time commitments and, for some, pain. PE
observed that scans and consultations were scheduled “one
thing at a time” in contrast to being co-ordinated into
sequential events in the one location or on the one day. He
found it tiring to keep up his commitments in other areas
of his life. PF described his pain as shifting from a “three”
to a “ten” when moving from lying to sitting to standing
during physical examinations. He found that getting in and
out of the car to come to the hospital was very difficult
and distressing for him and his wife. For PG, an open lung
biopsy caused fresh problems: “Until last week when they took
a section of lung for a BRAF test no-one would have known I had a
serious illness. I felt good and looked fine. Now I’m in pain from the
wound and the nerve damage.”
Information pathways and knowledge absorption
Though participants showed interest when clinicians and
technicians explained scanning equipment and the
meaning of visually represented results, most found it
challenging to understand and absorb the information. Six
of the seven participants interchangeably referred to CTs
(Computed Tomography), MRIs (Magnetic Resonance
Imaging) and PET (Positron Emission Tomography)
scans, or referred to them generically as ‘scans’. PB
expressed personal concern, and concern for others, about
the difficulties of staying focused during consultations:
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“Because you're the person with the problem, you won't actually hear
what the doctor is actually saying. Your partner has got to be primed
up … ask them to listen for you because you won't be able to listen.”
Most participants did not do background reading beyond
the information provided by hospital and individual
clinicians: “I'm an absolute outsider as far as medical things are
concerned even though I’ve been through all this before. I'm not like
some friends who search, trawl the Internet to get information. I don't
do that.” (PG). Some were concerned with the negative
implications of ‘knowing too much’: “To tell you the truth,
they said to read up about it on the internet but it's scary stuff when
you start reading and … being negative just feeds it, got to be positive
in it.” (PC)
Impacts of diagnosis
Four of the seven participants (PB, PD, PE, and PG)
appreciated the final diagnoses of metastasized melanoma
as a result of coincidence and luck. PD, for example,
noted: “If I hadn't have fallen down the stairs and been taken to
hospital and had the scan, I wouldn't have known I had it… I've
just been really lucky.”
Participants also expressed a range of emotions, from
devastation through to resignation, that “the beast was back”.
PD described her “shock” that she had been given the “all
clear” and yet had been diagnosed again: “Every time I have
one removed, you think there's going to be no more, this is my last
and low and behold, I've got more. So, it's just pretty invasive.” PB
commented that he had been expecting a recurrence: “I
was essentially cleared. But I always had the view in my subconscious
that … it could come back.”
Relational aspects of care during investigation and diagnosis
Participants’ relationships and communication with
clinicians and with healthcare providers was a prominent
aspect of the Identification phase of the journey. PA
deified her oncologist: “As far as I’m concerned, you’re god.
Whatever you say to do, I’ll do.” PE expressed a sense of great
fortune in having both an oncologist and ophthalmologist
as allies: “I'm just so lucky. Heavens above, to have these two
specialists … Honestly, I nearly cry sometimes. They're so good and
do everything for you.” PF wanted to know his life expectancy
but excused his oncologist from having to make an
accurate prediction: “I know it's impossible to answer, but how
long have I got? ... Just a rough ball park, that's all I want to
know.” PD empathized with the oncology nurses who had
to navigate her collapsed veins: “I feel sorry for them taking
blood … they don’t like having to do it. Causing me pain. I try to
make it easy on them. ‘Don’t worry’, that sort of thing.” PG was
more critical and struggled with the impact of
communication gaps between practitioners: “They're not in
touch with each other and you sort of feel … a link in the chain is
broken, and so again it's that feeling of powerlessness.”
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3. Action: Treatment, palliation, threat of death
The third segment featured sets of events that filtered out
ambiguities and narrowed down treatment options. During
this segment, two participants died (PA and PF), which
highlighted the time-critical nature of events in melanoma.
Treatment options included systemic treatment—
medications injected or ingested to shrink or control the
tumours—and locoregional treatment such as radiotherapy
directed towards a specific problem area such as the brain
or bones. Other options focused on palliative care, aiming
to minimize the symptoms from the tumours. Our
findings identified four key sets of experiences within this
segment.
Treatment decisions
Most participants assumed they would take some kind of
therapeutic action. “Both mum and dad were clear about the fact
that we should do all we can.” (family of PA). PF chose not to
be involved in decision-making, saying to the oncologist:
“You make all the decisions for me and I go along with whatever you
say.” PG described his approach as being one of choosing
quality care and then following the directions of those with
expertise. The option of seeking second opinions on
treatment decisions was raised by two participants. PB
noted: “People … probably don't necessarily realise that they have a
choice.” PG described his oncologist as being very open to a
second opinion: “He told me what he would be planning to do but
also urged me to make contact with Q [oncologist at another
treatment facility] and he wrote a referral.”
Response to BRAF testing
The wait time of up to four weeks for BRAF test results,
which decide whether a particular type of systemic
treatment would work, was a cause of concern for
participants because it delayed treatment decisions.
Participants described being “annoyed” by the wait and
described the waiting period as “suspended animation” and
“limbo”.
Though participants commented that BRAF testing had
been explained well to them, few made reference to the
term ‘BRAF’ in their descriptions of their circumstances,
instead referring to ‘the test’ or adopting an analogy used
by the oncologist: “We're struggling to find out what the on and
off switch is” (family of PA). Participants equated positive
BRAF results with a treatment consisting of a course of
tablets, whereas they equated immuno-therapy with a
treatment involving a course of injections or “chemo”
therapy. PD commented: “It was either tablets or injections and
he [oncologist] did a test and he's decided the injections were a better
way to go for this.”
Physical and psychosocial experiences of treatment
All participants expected to experience difficulties in
receiving treatment. Most described being well prepared
for immune-therapy treatment and its potential side effects
through information pamphlets and tours of treatment
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facilities. Hair loss after radiation to the tumour on her
skull was described by PA as being of minimal concern.
PD was satisfied that the “lumps” and “red marks” on her
arms and legs were “routine for the treatment.” Two
participants described uncertainty about the side effects
they were experiencing. PG was not sure whether his
itchiness was a side effect of treatment or a heat rash, but
decided against informing his oncologist because the
symptoms were controllable and quickly dissipated, and
because he did not want treatment to stop. PB, on a
clinical trial for Dabrafenib (a drug improving progressionfree survival of patients with advanced melanoma with
mutations in the BRAF gene), was uncertain about the
permanence of almost immediate side effects that included
curly hair, body aches, fatigue and additional layers of skin
on his feet that had to be “shaved off” every six weeks. He
rationalized concern about these effects against the fact
that his tumours were shrinking significantly.
PB described the time commitment of his clinical trial as
“significant”, comprising attendance at the hospital research
unit every three to four weeks for a period of over five
years, with a subsequent trial requiring him to travel to the
hospital occasionally and be in contact by phone. He
noted that he would have “lost sight of the objective” if not for
the support of friends and family.
Relational aspects of care during treatment
In the Action phase all participants conveyed a heavy
reliance on their oncologist. PA expressed to her
oncologist the personal importance of his treatment plan:
“You’ve no idea how much hope you’ve given me, and all my family,
because they’ve all just dropped their bundles …” PD identified
her oncologist’s reputation as a basis for trust in her
treatment: “He's got a good success rate apparently so there's every
chance that it's going to go [right].” PF gave his oncologist
discretionary power over his treatment and relieved him of
the burden of treatment failure: “I have every confidence in
yourself … If it works out good, if it works out bad, it doesn't
matter, because I know you're doing your best.”
On the other hand, PG expressed concern that
information about his health status had not been well
curated and communicated: “After the last scans [following a
first round of Keytruda, an immunotherapy drug], I found out I have
tumours I was never told about …. I was told I had them all the
way along. Maybe they didn’t see those tumours as relevant ... I
assumed they had told me everything.”
4. Adaption: Tumour surveillance and treatment side
effects
Of the four participants who progressed into definitive
treatment, two transitioned out of the treatment phase and
were adapting to their ‘new normal’ by the close of the
study. Their descriptions and reflections on key care
experiences at this point comprise the following issues.
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Health management related to surgery and medication
As a result of extensive surgery to remove all lymph nodes
in the left leg as far as the vena cavae, PB developed
significant lymphedema. Each night and on vacation he
pumped fluid from his leg, and every six to eight weeks he
visited a lymphoedema physiotherapist to ensure his leg
was being well managed. Side effects from the drug
Dabrafenib received while on clinical trial continued to
affect PB, though the addition of a second drug,
Trametinib (a drug with a different mechanism that helps
prolong the benefits of Dabrafenib) had largely rectified
the side effects of the first drug. He rationalized the
impact of side effects as a “small price to pay” for the
survival longevity the trial drugs had provided him: “My
feet are still a bit sore, some joints become inflamed—my eyesight is
not as good as it was, by a long shot. But I am still alive after seven
years on Dabrafenib and now in combo with Trametinib drugs!”
Tumour surveillance and dependence on healthcare services for life
decisions
PB had scans every six months “and then I have a phone call
from X [oncologist] and I find out whether I am going to live or die.
I refuse to be down about it. You can’t look inward and feel sorry for
yourself, it will serve no purpose.”
At a follow-up consultation a year after surgery to remove
most of the lymph nodes in his right arm, PC sought a
second opinion regarding the completion of a tattoo on
that arm: “I just got one half done and I wanted to get it finished
… He said I can't get it done because I've had my glands removed.
Is that correct?”

Discussion
The aim of this research was the exploration, description
and thematic interpretation of seven unique sets of
encounters with health care provision in the context of
advanced and metastatic melanoma. While entry into the
system and the journey along pathways of care from
patients’ perspectives are markedly non-routine, our
thematic analysis of the data identified four key transitional
segments in the commonality of experiences.
In this four-segment trajectory model, the second and
third segments represent the critical periods of
participants’ healthcare trajectories, based on rich data
which contrast with the ‘bookends’ of the first and fourth
segments. The four-phase model encompasses phases of
Initiation, Identification, Action and Adaption and reflects
the experience of advancement, recurrence or metastases
of the disease and the high likelihood of further
recurrence. This is differentiated from a model which
suggest that populations of people go through a largely
linear progression of disease management resulting in cure
or disease stasis.

metastatic melanoma to seek healthcare. It points to a
need for information and education about metastases from
melanoma.
The second segment, Identification, highlights the
complexity of diagnostic pathways related to metastatic
melanoma. It features needs for individualized compassion
and responsiveness in the delivery of medical care,
underlined by participants’ concern with the physical and
logistical demands of appointments and consultations.
This stage is also characterized by participants’ perceptions
of doctors as allies, mentors and oracles in the decisionmaking process.
The personal impact of timeliness features in the third,
Action, segment. The wait times for BRAF test results
contrasted with participants’ perceived urgency in forming
decisive pathways for the management of the disease,
creating a ‘hurry up and wait’ dynamic in their trajectory of
care. Diagnosis occurring after surveillance programs had
been completed—sometimes just weeks after participants
had been given the ‘all clear’—points to a possible need
for extended periods of intensive surveillance.
The final segment, Adaption, reflects the distinctly circular
nature of the care pathway for this patient population. For
the two surviving participants, life is forever characterised
by the reliance on healthcare services to treat remaining
tumours, diagnose new tumours and manage the side
effects of past and present therapies. Some patient-focused
domains emerged as relevant: the need for personalized
care for ongoing pain, lack of mobility and lymphedema as
a result of the consequences of surgery and chemical
treatment; and compassion from healthcare professionals
in relation to the ongoing threat to life imposed by a lack
of cure for metastatic melanoma.

Limitations

We believe this to be the first study to locate patients’
experiences of recurrent, advanced and metastatic
melanoma as a meta-view of the clinical trajectory. One
limitation is the small size of the participant group,
although paradoxically this allows for the fashioning of a
richer descriptive account. A small cohort makes detailed
experiential data available for inspection and facilitates
understanding of care from multiple vantage points.
Correspondingly, it limits the extent to which the data is
representative of others.
Data of this type is not standardised, but adaptive to each
participant’s state of health, living situation and availability.
Given the health situations of the individual participants,
we did not study other aspects of the participants’ lives,
including any comorbidities.

The first segment, Initiation, draws attention to the non
skin-related issues that drive people with advanced and
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Conclusion
This study contributes a model of this patient population’s
shifting responses to clinical journeys with advanced or
metastatic melanoma. The model features a cyclical
dynamic that is distinguishable from the ideal linear
progression through diagnosis, treatment and onto longterm surveillance. People with advanced and metastatic
melanoma must adapt to the side-effects and collateral
damage of initial and ongoing treatment and live with the
perspective that renewed healthcare concerns are not a
matter of ‘if’ but ‘when’.
Our participants perceived the clinicians they interacted
with, and particularly their oncologist, not only as medical
experts but also as co-curators of their lives. Clinicians’
choices influenced the quality of their survivorship, down
to such details as whether or not they can complete an
unfinished tattoo.
Our findings offer to various stakeholder groups in health
care an understanding of the need for longitudinal personcentered services to support this growing patient
population. The typology may have merit beyond our
patients and may encapsulate other clinical trajectories in a
range of chronically life-threatening diseases.
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